Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne L Peters

Showing results (21-30 of 125) with videos related to

Pageof 13
Sort By:
Annals of Emergency Medicine|November 15, 2013
Trial to examine text message-based mHealth in emergency department patients with diabetes (TExT-MED): a randomized controlled trialSanjay Arora, Anne L Peters, Elizabeth Burner, et al.
Journal of the Endocrine Society|October 17, 2018
Advances in Glucose Monitoring and Automated Insulin Delivery: Supplement to Endocrine Society Clinical Practice GuidelinesAnne L Peters, Andrew J Ahmann, Irl B Hirsch, et al.
Diabetes Care|June 18, 2026
Impact of Prior Authorization Suspension on Access to Diabetes Technology in an Underserved Population: A Retrospective AnalysisValerie Ruelas, Mallory Bernstein, Jaquelin Flores Garcia, et al.
Diabetes Spectrum : a Publication of the American Diabetes Association|September 9, 2022
Equity in Medical Care for People Living With DiabetesJaquelin Flores Garcia, Anne L Peters, Jennifer K Raymond, et al.
BMJ Open Diabetes Research & Care|September 27, 2017
Engagement and outcomes in a digital Diabetes Prevention Program: 3-year updateS Cameron Sepah, Luohua Jiang, Robert J Ellis, et al.
Diabetes Technology & Therapeutics|August 1, 2012
Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured populationJohn A Romley, Dana P Goldman, Matthew Solomon, et al.
Diabetes, Obesity & Metabolism|March 30, 2019
Baseline nocturnal glucose change: A predictor of the treatment effect of bolus intensification in insulin-treated type 2 diabetesAnne L Peters, Milivoj Piletič, Johan Ejstrud, et al.
Diabetes Care|December 1, 2016
The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 DiabetesHelena W Rodbard, Anne L Peters, April Slee, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|September 5, 2015
BIOSIMILARS AND NEW INSULIN VERSIONSAnne L Peters, R Daniel Pollom, Jason S Zielonka, et al.
Journal of Diabetes Science and Technology|January 30, 2023
Blue Circle Health: A Novel Patient-Centered Model of Health Care Delivery for Low-Income Patients With Type 1 DiabetesBrittany S Bruggeman, Ashby F Walker, Anne L Peters, et al.
Pageof 13

Showing results (21-30 of 125) with videos related to

Sort By:
Pageof 13
Annals of Emergency Medicine|November 15, 2013
Trial to examine text message-based mHealth in emergency department patients with diabetes (TExT-MED): a randomized controlled trialSanjay Arora, Anne L Peters, Elizabeth Burner, et al.
Journal of the Endocrine Society|October 17, 2018
Advances in Glucose Monitoring and Automated Insulin Delivery: Supplement to Endocrine Society Clinical Practice GuidelinesAnne L Peters, Andrew J Ahmann, Irl B Hirsch, et al.
Diabetes Care|June 18, 2026
Impact of Prior Authorization Suspension on Access to Diabetes Technology in an Underserved Population: A Retrospective AnalysisValerie Ruelas, Mallory Bernstein, Jaquelin Flores Garcia, et al.
Diabetes Spectrum : a Publication of the American Diabetes Association|September 9, 2022
Equity in Medical Care for People Living With DiabetesJaquelin Flores Garcia, Anne L Peters, Jennifer K Raymond, et al.
BMJ Open Diabetes Research & Care|September 27, 2017
Engagement and outcomes in a digital Diabetes Prevention Program: 3-year updateS Cameron Sepah, Luohua Jiang, Robert J Ellis, et al.
Diabetes Technology & Therapeutics|August 1, 2012
Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured populationJohn A Romley, Dana P Goldman, Matthew Solomon, et al.
Diabetes, Obesity & Metabolism|March 30, 2019
Baseline nocturnal glucose change: A predictor of the treatment effect of bolus intensification in insulin-treated type 2 diabetesAnne L Peters, Milivoj Piletič, Johan Ejstrud, et al.
Diabetes Care|December 1, 2016
The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 DiabetesHelena W Rodbard, Anne L Peters, April Slee, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|September 5, 2015
BIOSIMILARS AND NEW INSULIN VERSIONSAnne L Peters, R Daniel Pollom, Jason S Zielonka, et al.
Journal of Diabetes Science and Technology|January 30, 2023
Blue Circle Health: A Novel Patient-Centered Model of Health Care Delivery for Low-Income Patients With Type 1 DiabetesBrittany S Bruggeman, Ashby F Walker, Anne L Peters, et al.
Pageof 13